University of California, San Diego |
Tannishtha Reya |
Inception - Discovery Stage Research Projects |
Reprogramming human stem cells for blood cell generation |
$210,060 |
University of California, Irvine |
Janet Baulch |
Inception - Discovery Stage Research Projects |
An exosome-based translational strategy to mitigate Alzheimer’s disease neuropathology |
$157,650 |
American Association of Blood Banks |
Naynesh Kamani |
Conference II |
15th International Cord Blood Sympsium |
$30,000 |
Stanford University |
Samuel Strober |
Conference II |
Third International Workshop on Clinical Tolerance |
$29,500 |
University of California, Los Angeles |
Song Li |
Conference II |
The 18th Annual UC System-Wide Bioengineering Symposium |
$25,000 |
University of California, San Diego |
Karen Christman |
Therapeutic Translational Research Projects |
Injectable pro-regenerative scaffold for treating symptomatic peripheral artery disease |
$2,839,317 |
Stanford University |
Joseph Wu |
Tool Translational Research Projects |
A Novel, Robust and Comprehensive Predictive Tool Using Human Disease-Specific Induced Pluripotent Stem Cells for Preclinical Drug Screening |
$975,000 |
Cellular Biomedicine Group, Inc. |
Jack Wang |
Late Stage Preclinical Projects |
Allogenic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis |
$1,200,000 |
Caladrius Biosciences |
William Sietsema |
Clinical Trial Stage Projects |
Phase 2 Safety and Efficacy Study of CLBS03 Autologous T-Regulatory Cells in Adolescents with Recent Onset Type 1 Diabetes Mellitus |
$8,175,946 |
Cedars-Sinai Medical Center |
Clive Svendsen |
Clinical Trial Stage Projects |
Human Neural Progenitors Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis |
$6,154,067 |
St. Jude Children's Research Hospital |
Stephen Gottschalk |
Clinical Trial Stage Projects |
Lentiviral Gene Therapy for Infants with X-linked Severe Combined Immunodeficiency using Autologous Bone Marrow Stem Cells and Busulfan Conditioning |
$11,924,780 |
Stanford University |
Joseph Wu |
Conference II |
2017 Stanford Drug Discovery and Stem Cell Technology Conference |
$2,359 |
City of Hope, Beckman Research Institute |
John Zaia |
Conference - The 2017 Alpha Stem Cell Clinic Annual Symposium |
2nd Annual Symposium of the CIRM Alpha Stem Cell Clinics Network
"Alpha Clinics - Making the Future a Reality for Stem Cell-Based Therapies" |
$79,287 |
Stanford University |
Roel Nusse |
Quest - Discovery Stage Research Projects |
Preclinical development of human hepatocyte progenitor cells for cell therapy |
$1,651,211 |
University of California, Irvine |
Leslie Thompson |
Quest - Discovery Stage Research Projects |
hNSC-mediated delivery of ApiCCT1 as a candidate therapeutic for Huntington’s disease |
$1,650,263 |
Gladstone Institutes, J. David |
Deepak Srivastava |
Quest - Discovery Stage Research Projects |
Direct Cardiac Reprogramming for Regenerative Medicine |
$2,392,157 |
Parkinson's Institute |
Birgitt Schuele |
Quest - Discovery Stage Research Projects |
CRISPR/dCas9 mutant targeting SNCA promoter for downregulation of alpha-synuclein expression as a novel therapeutic approach for Parkinson’s disease |
$1,288,415 |
University of California, San Diego |
Dan Kaufman |
Quest - Discovery Stage Research Projects |
Targeted off-the-shelf immunotherapy to treat refractory cancers |
$1,936,936 |
University of California, Los Angeles |
John Chute |
Quest - Discovery Stage Research Projects |
Protein tyrosine phosphatase - sigma inhibitors for hematopoietic regeneration |
$2,116,708 |
University of California, San Francisco |
Julie Sneddon |
Quest - Discovery Stage Research Projects |
Designing a cellular niche for transplantation of human embryonic stem cell-derived beta cells |
$2,006,076 |
Stanford University |
Matthew Porteus |
Quest - Discovery Stage Research Projects |
Genome Editing to Correct Cystic Fibrosis Mutations in Airway Stem Cells |
$1,968,456 |
University of California, San Diego |
Alysson Muotri |
Quest - Discovery Stage Research Projects |
A treatment for Zika virus infection and neuroprotection efficacy |
$1,924,524 |
Stanford University |
Rosa Bacchetta |
Quest - Discovery Stage Research Projects |
GENE EDITING FOR FOXP3 IN HUMAN HSC |
$984,228 |
University of California, San Francisco |
Tejal Desai |
Quest - Discovery Stage Research Projects |
Thin Film Encapsulation Devices for Human Stem Cell derived Insulin Producing Cells |
$1,092,063 |
jCyte, Inc |
Henry Klassen |
Clinical Trial Stage Projects |
Phase 2b Clinical Study of Safety and Efficacy of Intravitreal Injection of Retinal Progenitor Cells (jCell) for Treatment of Retinitis Pigmentosa |
$8,295,750 |
Stanford University |
Robert Lowsky |
Clinical Trial Stage Projects |
Induction of Tolerance to Combined Kidney and Hematopoietic Progenitor Cell Transplants from HLA Haplotype Matched Living Donors |
$6,653,266 |
Ankasa Regenerative Therapeutics |
Ying Zhu |
Therapeutic Translational Research Projects |
An autologous somatic stem cell therapy for the treatment of osteonecrosis |
$2,088,780 |
University of Southern California |
Denis Evseenko |
Therapeutic Translational Research Projects |
Pluripotent stem cell-derived chondrocytes for articular cartilage repair |
$2,503,104 |
UCSF Benioff Children’s Hospital Oakland |
Mark Walters |
Therapeutic Translational Research Projects |
Curing Sickle cell Disease with CRISPR-Cas9 genome editing |
$4,394,276 |
University of California, San Francisco |
Mark Walters |
Therapeutic Translational Research Projects |
Curing Sickle cell Disease with CRISPR-Cas9 genome editing |
$60,635 |
Gladstone Institutes, J. David |
Yadong Huang |
Therapeutic Translational Research Projects |
Human iPSC-derived GABAergic Progenitors for Alzheimer’s Disease Treatment |
$1,900,000 |
City of Hope, Beckman Research Institute |
Paul Salvaterra |
Conference - Manage The SPARK Annual Meeting |
Manage the 2017 SPARK Annual Meeting |
$22,555 |
University of Southern California |
Justin Ichida |
Conference II |
The 7th Annual California ALS research network and PAC10 meeting |
$10,830 |
Orchard Therapeutics plc |
Leslie Meltzer |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$2,638,745 |
University of California, Los Angeles |
Donald Kohn |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$5,827,000 |
University of California, Los Angeles |
Donald Kohn |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$10,156,925 |
Cedars-Sinai Medical Center |
Michael Lewis |
Clinical Trial Stage Projects |
Pulmonary Arterial Hypertension Treated with Cardiosphere-Derived Allogeneic Stem Cells |
$7,354,772 |
San Diego State University Foundation |
Ralph Feuer |
Conference - Manage The Bridges Annual Meeting |
2017 Bridges Annual Meeting |
$153,449 |
IQVIA, Inc. |
Amritha Jaishankar |
Translating Center |
A Translating Center designed to expedite the development and delivery of high quality stem cell therapies to patients |
$15,000,000 |
University of California, San Diego |
Stephanie Cherqui |
Late Stage Preclinical Projects |
Ex vivo transduced autologous human CD34+ hematopoietic stem cells for treatment of cystinosis |
$5,273,189 |
Midwinter Conference of Immunologists |
Christel Uittenbogaart |
Conference II |
The 2017 Midwinter Conference of Immunologists at Asilomar |
$5,000 |
University of California, San Diego |
Robert Sah |
Conference II |
2016 Tissue Engineering and Regenerative Medicine International Society - Americas (TERMIS-AM) Conference in San Diego, CA on December 11-14, 2016 |
$40,000 |
Vitalant Research Institute |
Shibani Pati |
Conference II |
Cellular Therapies and Transfusion Medicine in Trauma and Critical Care - Looking Towards the Future |
$30,000 |
Alliance Forum Foundation |
George Hara |
Conference II |
2016 World Alliance Forum in San Francisco (WAFSF) “US-Japan Innovative Healthcare Technologies Conference” |
$20,000 |
Gladstone Institutes, J. David |
Deepak Srivastava |
Quest - Discovery Stage Research Projects |
Use of Human iPSC-derived Endothelial Cells for Calcific Aortic Valve Disease Therapeutics |
$2,400,048 |
California Institute of Technology |
David Baltimore |
Quest - Discovery Stage Research Projects |
Immunotherapy for HIV infection using engineered hematopoietic stem/progenitor cells |
$1,569,193 |
ViaCyte, Inc. |
Kevin D'Amour |
Late Stage Preclinical Projects |
Stem cell-derived islet cell replacement therapy with immunosuppression for high-risk type 1 diabetes |
$3,544,721 |
Humacyte, Inc. |
Jeffrey Lawson |
Clinical Trial Stage Projects |
A Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison with ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) |
$7,625,000 |
University of California, Los Angeles |
April Pyle |
Quest - Discovery Stage Research Projects |
CRISPR/Cas9 nanoparticle enabled therapy for Duchenne Muscular Dystrophy in muscle stem cells |
$2,150,400 |
Stanford University |
Hiromitsu Nakauchi |
Quest - Discovery Stage Research Projects |
Novel Rejuvenated T Cell Immunotherapy for Lung Cancer |
$1,968,456 |
University of California, Berkeley |
David Schaffer |
Quest - Discovery Stage Research Projects |
Scalable, Defined Production of Oligodendrocyte Precursor Cells to Treat Neural Disease and Injury |
$1,627,099 |
University of California, Davis |
David Segal |
Quest - Discovery Stage Research Projects |
MSC delivery of an artificial transcription factor to the brain as a treatment for Angelman Syndrome |
$1,055,319 |
Scripps Research Institute |
Jeanne Loring |
Quest - Discovery Stage Research Projects |
Autologous cell therapy for Parkinson’s disease using iPSC-derived DA neurons |
$2,299,786 |
IQVIA, Inc. |
Peter Robinson |
Accelerating Center |
An Accelerating Center designed to expedite the development and delivery of high quality stem cell therapies to patients |
$11,772,453 |
University of California, Los Angeles |
Sophie Deng |
Late Stage Preclinical Projects |
Regeneration of a Normal Corneal Surface by Limbal Stem Cell Therapy |
$4,244,211 |
University of California, Los Angeles |
Brigitte Gomperts |
Conference - Lung Regenerative Medicine Workshop |
Stem Cells for Lung Diseases - Overcoming Barriers to Find New Therapies |
$44,548 |
University of California, San Francisco |
Holger Willenbring |
Inception - Discovery Stage Research Projects |
Generation of bile duct-competent transplantable human liver organoids |
$206,460 |
Cedars-Sinai Medical Center |
Linda Cambier |
Inception - Discovery Stage Research Projects |
Exosomal Y-RNAs as mediators of bioactivity of cardiac-derived cell therapy |
$181,063 |
Cedars-Sinai Medical Center |
Clive Svendsen |
Inception - Discovery Stage Research Projects |
Blood Brain Barrier (BBB)-on-Chip: Development and validation of a novel iPS-based microfluidic model of the human BBB |
$241,992 |
Stanford University |
Phillip Yang |
Inception - Discovery Stage Research Projects |
Activation of patient-specific endogenous myocardial repair through the exosomes generated from the hypoxic iPSC-derived cardiomyocytes (iCMs). |
$234,619 |
University of California, Los Angeles |
Bennett Novitch |
Inception - Discovery Stage Research Projects |
Organoid Modeling of Human Cortical Microcircuits |
$208,916 |
University of California, San Francisco |
Andrew Brack |
Inception - Discovery Stage Research Projects |
Examining the efficacy of GDF11 antibody as a rejuvenator of aged human muscle stem cell capacity and muscle repair . |
$180,000 |
University of California, Los Angeles |
April Pyle |
Inception - Discovery Stage Research Projects |
Novel Platforms to Enhance In Vivo Delivery of Skeletal Muscle Progenitor Cells from Human Pluripotent Stem Cells |
$230,400 |
Stanford University |
Albert Wong |
Therapeutic Translational Research Projects |
2nd Generation Vaccine for the Treatment of Glioblastoma |
$2,929,889 |
University of California, San Diego |
Alysson Muotri |
Inception - Discovery Stage Research Projects |
Reverse transcriptase inhibitors as a novel therapeutic approach for neurological autoimmune disorders |
$210,060 |
University of California, Los Angeles |
Owen Witte |
Inception - Discovery Stage Research Projects |
Identification of stem cell surface markers as potential therapeutic targets for advanced prostate cancer |
$209,160 |
Stanford University |
Jeffrey Goldberg |
Inception - Discovery Stage Research Projects |
Embryonic Stem Cells for Corneal Endothelial Degeneration |
$235,836 |
Vitalant Research Institute |
Marcus Muench |
Inception - Discovery Stage Research Projects |
Modulating Liver Sinusoidal Endothelial Cell Permeability to Enhance Engraftment of Endothelial Cell Progenitors for the Treatment of Hemophilia A |
$180,000 |
Children's Hospital of Los Angeles |
Senta Georgia |
Inception - Discovery Stage Research Projects |
Developing a personalized approach to beta cell replacement for patients with a genetic form of diabetes |
$179,995 |
University of California, San Diego |
Karl Wahlin |
Inception - Discovery Stage Research Projects |
Microenvironment based optimization of retinal induction using CRISPR-CAS9 reporter pluripotent stem cells as an expandable source of retinal progenitors and photoreceptors. |
$232,200 |
University of California, Los Angeles |
Stanley Carmichael |
Inception - Discovery Stage Research Projects |
iPS-Interneuron Transplantation for Neural Repair after Stroke |
$229,396 |
Stanford University |
Bertha Chen |
Inception - Discovery Stage Research Projects |
Autologous iPSC-based therapy for radiation induced bladder injury |
$235,836 |
University of California, San Diego |
Dionicio Siegel |
Inception - Discovery Stage Research Projects |
New Methods for the Chemical Expansion of Hematopoietic Stem and Progenitor Cells |
$232,200 |
Stanford University |
Philip Beachy |
Inception - Discovery Stage Research Projects |
Curing bladder cancer by replacing corrupted urothelium with differentiated hES cells |
$210,906 |
University of California, Berkeley |
Jacob Corn |
Inception - Discovery Stage Research Projects |
Genome editing for causation and reversion of MPN-associated mutations in human hematopoietic stem cells |
$235,800 |
University of California, Los Angeles |
Arjun Deb |
Inception - Discovery Stage Research Projects |
Targeting progenitors in scar tissue to reduce chronic scar burden |
$230,400 |
International Society for Experimental Hematology |
David Traver |
Conference II |
International Society for Experimental Hematology, 45th Annual Scientific Meeting |
$25,000 |
American Association of Blood Banks |
Naynesh Kamani |
Conference II |
14th International Cord Blood Symposium: Give Life Twice |
$15,000 |
Keystone Symposia on Molecular and Cellular Biology |
Thale Jarvis |
Conference II |
Neurogenesis during Development and in the Adult Brain (joint with Transcriptional and Epigenetic Control in Stem Cells) |
$35,000 |
University of California, Irvine |
LESLIE Thompson |
Conference II |
HD-CARE INAUGURAL SYMPOSIUM |
$1,500 |
Children's Hospital of Los Angeles |
Mark Frey |
Therapeutic Translational Research Projects |
ASCENT- Advanced Stem Cell Enteric Neuropathy Therapy |
$7,077,352 |
University of California, Davis |
Joseph Anderson |
Therapeutic Translational Research Projects |
Overexpression of HexA/HexB by lentivector expression in blood cells to treat Tay-Sachs and Sandhoff disease |
$883,174 |
City of Hope, Beckman Research Institute |
Yanhong Shi |
Therapeutic Translational Research Projects |
Process development for establishing an iPSC-based therapeutic candidate for Canavan disease |
$7,377,384 |
Capricor, Inc |
Linda Marban |
Clinical Trial Stage Projects |
Allogeneic Cardiosphere-Derived Cells for Duchenne Muscular Dystrophy Cardiomyopathy |
$3,376,259 |
University of California, Los Angeles |
Lili Yang |
Therapeutic Translational Research Projects |
Stem Cell-Based iNKT Cell Therapy for Cancer |
$6,956,775 |
University of California, San Diego |
Lawrence Goldstein |
Therapeutic Translational Research Projects |
Human Embryonic Stem Cell-Derived Neural Stem Cell Transplants in Amyotrophic Lateral Sclerosis |
$1,790,000 |
Semma Therapeutics |
Felicia Pagliuca |
Therapeutic Translational Research Projects |
Personalized Cell Therapy for Diabetes |
$597,333 |
University of California, San Francisco |
Jennifer Puck |
Late Stage Preclinical Projects |
Ex Vivo Transduction of the Human Artemis (DCLRE1C) cDNA by Lentiviral Vector AProArt into CD34+ Hematopoietic Cells for Artemis (ART)-Deficient Severe Combined Immunodeficiency (SCID) |
$4,268,865 |
University of California, Los Angeles |
Peter Butler |
Therapeutic Translational Research Projects |
Personalized Cell Therapy for Diabetes |
$1,494,896 |
Mosaic Event Management, Inc. |
Ron Johnson |
Conference - Manage The 2016 Bridges And SPARK Annual Meetings |
2016 CIRM Bridges & SPARK Meetings |
$205,388 |
Angiocrine Bioscience, Inc. |
Paul Finnegan |
Late Stage Preclinical Projects |
Development of AB-110: genetically-modified endothelial cells plus expanded cord blood hematopoietic stem cells as a transplantation therapy |
$3,797,117 |
University of California, San Diego |
Catriona Jamieson |
Conference - The 2016 Alpha Stem Cell Clinic Annual Symposium |
UCSD Division of Regenerative Medicine and CIRM Alpha Clinics Network Symposium |
$37,778 |
Cal State Univ, Long Beach |
Lisa Klig |
Bridges |
CIRM Stem Cell Biotechnology Training Program |
$2,919,901 |
California Institute of Technology |
Henry Lester |
SPARK |
CIRM Early Investigators High School Stem Cell Research Program |
$132,717 |
Cal Poly Corporation, an Auxiliary of California Polytechnic State University, San Luis Obispo |
Trevor Cardinal |
Bridges |
Interdisciplinary Master of Science Program in Regenerative Medicine |
$2,556,199 |
Cal State Univ, Sacramento |
Lisa Hammersley |
Bridges |
Strengthening the Pipeline of Master's-level Scientific and Laboratory Personnel in Stem Cell Research |
$2,049,679 |
San Francisco State University |
Lily Chen |
Bridges |
CIRM Bridges 2.0: Training the Next Generation of Stem Cell Scientists |
$2,958,876 |
SJSU Research Foundation |
Tzvia Abramson |
Bridges |
SCILL- Stem Cell Internships in Laboratory-based Learning |
$3,086,302 |
Humboldt State University Sponsored Programs Foundation |
Jacob Varkey |
Bridges |
CIRM 2.0 Bridges Training Program |
$2,534,223 |
Pasadena City College |
Pamela Eversole-Cire |
Bridges |
Bridges to Stem Cell Research and Therapy at Pasadena City College |
$2,522,591 |